Hims & Hers Health, Inc. (HIMS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

Core Insights - The stock has increased nearly 12% since the last check-in in May, indicating positive market performance [1] Group 1: Analyst Background - Undercovered Deep Insights is led by Moz Farooque, a seasoned market analyst with experience in financial journalism and modeling [1] - Moz Farooque's research has been featured on various financial platforms, showcasing his expertise in identifying stock and crypto opportunities [1] - He is a Fellow Member of ACCA and holds a BSc in Applied Accounting and Finance from Oxford Brookes University [1]

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, particularly related to misrepresentation of a partnership with Novo Nordisk [1][2]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company misrepresented the nature of its partnership with Novo Nordisk, claiming it could sell both Wegovy and compounded semaglutide, and asserted compliance with FDA regulations [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, a decline of over 34%, from $64.22 to $41.98 per share [5].

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS) between April 29, 2025 and June 22, 2025, inclusive. Should You Join This Class Action Lawsuit? If you purchased or acquired Hims securities, and/or would like to discuss your legal rights and options please visit Hims & Hers H ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims related to deceptive practices in promoting and selling medications [1][2][3] Group 1: Lawsuit Details - The class action lawsuit, titled Sookdeo v. Hims & Hers Health, Inc., involves purchasers of Hims & Hers securities from April 29, 2025, to June 23, 2025, with a deadline of August 25, 2025, for seeking lead plaintiff status [1][4] - Allegations include that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - Following the termination of its partnership with Novo Nordisk due to these allegations, Hims & Hers' stock price dropped by over 34% [3] Group 2: Company Background - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk on April 29, 2025, which was later terminated due to the aforementioned allegations [2][3] Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and is recognized as a leading law firm in securities fraud and shareholder litigation [5] - The firm has a strong track record, having recovered over $2.5 billion for investors in 2024 alone, and has been ranked 1 in securing monetary relief for investors [5]

Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and safety concerns during the specified Class Period [1][3]. Group 1: Allegations Against Hims & Hers - The complaints allege that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which posed risks to patient safety [3]. - It is claimed that there was a substantial risk of termination of Hims & Hers' collaboration with Novo Nordisk due to these practices [3]. - The positive statements made by the company regarding its business and operations were deemed materially misleading and lacked a reasonable basis [3]. Group 2: Legal Process and Participation - Investors in Hims & Hers have until August 25, 2025, to seek appointment as lead plaintiff representatives in the class action [4]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the class [4]. - Investors can choose to participate actively or remain absent from the proceedings without affecting their ability to share in any recovery [4]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [5]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013, recovering hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims misrepresented the nature of its collaboration with Novo and the offerings of compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell the weight loss drug Wegovy on its platform [3]. - Allegations include misrepresentation of the partnership with Novo Nordisk, claiming compliance with FDA regulations regarding the sale of compounded semaglutide [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement on June 23, 2025, that it was terminating the partnership due to Hims & Hers' deceptive practices, the company's stock price fell by $22.24 per share, a decline of over 34% [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2] - It is alleged that this situation created a significant risk of termination of the collaboration between Hims and Novo Nordisk [2] - The defendants' positive statements regarding the company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing substantial recoveries for shareholders and has been recognized as a top securities litigation firm in the United States for seven consecutive years [4]

Core Viewpoint - Hims & Hers Health, Inc. is experiencing a surge in retail investor interest, positioning it as a potential candidate for the next "meme stock" rally due to high short interest and social media attention [1] Group 1: Short Interest - Over 65 million shares of Hims & Hers, accounting for approximately 33.5% of its public float, are sold short, indicating a high level of short interest that makes it a target for a potential short squeeze [2] - This elevated short interest is significantly above average, attracting retail traders who often coordinate on social media platforms [2] Group 2: Social Media Buzz - Discussions surrounding Hims & Hers stock have surged nearly 1,000% in the past month, making it the twelfth most-mentioned stock on WallStreetBets [3] - The attention from individual investors is attributed to the company's innovative approach and brand equity, as noted by a trading behavior analyst [4] Group 3: Growth Potential - Analysts project Hims & Hers to achieve an EPS growth of nearly 178% in the next year, indicating strong growth potential that retail investors are keen to capitalize on [5] - The company has reported a significant revenue increase of 111% year-over-year and an expansion of its user base to 2.4 million subscribers, differentiating it from typical meme stocks [6] Group 4: Market Sentiment - Retail-driven momentum for Hims & Hers is expected to continue as long as the company maintains its growth, innovation, and user experience, alongside interest from institutional and online investors [7] - As of the latest publication, shares of Hims & Hers Health were up 0.79% at $57.7 [8]